These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Uncommon Presentation of Scleromyxoedema with a Distribution Pattern Mimicking a Photodermatosis. Kirchberger MC; Sticherling M; Erdmann M Acta Derm Venereol; 2017 Aug; 97(8):979-980. PubMed ID: 28421236 [No Abstract] [Full Text] [Related]
28. Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema. Baglama Š; Trčko K Acta Dermatovenerol Croat; 2020 Jul; 28(1):24-28. PubMed ID: 32650847 [TBL] [Abstract][Full Text] [Related]
29. High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. Guarneri A; Cioni M; Rongioletti F J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1157-1160. PubMed ID: 28370513 [TBL] [Abstract][Full Text] [Related]
30. Scleromyxedema: successful treatment with thalidomide in two patients. Amini-Adle M; Thieulent N; Dalle S; Balme B; Thomas L Dermatology; 2007; 214(1):58-60. PubMed ID: 17191049 [TBL] [Abstract][Full Text] [Related]
31. Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare. Rongioletti F; Cozzani E; Parodi A J Cutan Pathol; 2010 Oct; 37(10):1084-7. PubMed ID: 19638067 [TBL] [Abstract][Full Text] [Related]
34. Diffuse skin thickening and linear papules in a 59-year-old woman. Brelsford M; Mason A; Pariser R Arch Dermatol; 2012 Nov; 148(11):1317-8. PubMed ID: 23165842 [No Abstract] [Full Text] [Related]
35. Lichen myxedematosus: a case series focusing on clinical features, disease associations, and management. Atci T; Yazganoglu KD; Yonal I; Ekinci AP; Kaplan SG; Babuna G; Besisik S; Baykal C J Dtsch Dermatol Ges; 2017 Feb; 15(2):215-218. PubMed ID: 28084678 [No Abstract] [Full Text] [Related]
36. Scleromyxedema vs scleredema: a diagnostic challenge. Conde Fernandes I; Sanches M; Velho G; Lobo I; Alves R; Selores M Eur J Dermatol; 2011; 21(5):822-3. PubMed ID: 21771713 [No Abstract] [Full Text] [Related]
37. [Good response of scleromyxedema and dermato-neuro syndrome to treatment with intravenous immunoglobulins]. Bielsa I; Benvenutti F; Guinovart RM; Ferrándiz C Actas Dermosifiliogr; 2012 May; 103(4):317-20. PubMed ID: 21917233 [TBL] [Abstract][Full Text] [Related]
38. Scleromyxedema, a positive effect with thalidomide. Jacob SE; Fien S; Kerdel FA Dermatology; 2006; 213(2):150-2. PubMed ID: 16902294 [TBL] [Abstract][Full Text] [Related]
39. [Response to thalidomide in scleromyxedema]. Pascualini MF; Caballero Escuti G; Valente E; Kurpis M; Ruiz Lascano A Medicina (B Aires); 2013; 73(3):252-4. PubMed ID: 23732202 [TBL] [Abstract][Full Text] [Related]
40. Renal injury in scleromyxoedema due to monoclonal gammopathy associated C3 glomerulonephritis. Kao S; Silinsky Krupnikova SD; AlMackenzie M; Atefi G BMJ Case Rep; 2022 Nov; 15(11):. PubMed ID: 36450416 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]